Published: 2019-05-29

Clinicopathological study of benign and malignant ovarian tumours and the role of HER2/neu and ER expression in these tumours

Nidhi Verma, Kriti Grover, S. P. Sharma, Priya Gupta, Preeti Singh, Anshu Singh


Background: Ovarian cancers represent the 6th most common cancer among females and are the most common cause of death from gynaecological cancers in the world. The aim is to do clinicopathologic study of ovarian tumours along with evaluation of the expression of estrogen receptor (ER) and human epidermal growth factor receptor (HER2/neu).

Methods: A total of 85 cases of ovarian tumors were studied and immunohistochemistry was performed with specific antibodies against ER and HER2/neu as per standard protocol.

Results: In present study, surface epithelial tumours were the commonest type comprising 64 cases (75.2%), followed by Germ cell tumours, 17cases (20%) and sex cord stromal tumours, 04 cases (4.8%).Among the surface epithelial tumours , ER‑positive cases were higher in malignant (71.4%) tumours as compared to borderline tumours (33.3%) and benign tumours (7.7%) while Her2/neu positive cases were higher in borderline (66.7%) tumours as compared to malignant tumours (42.9%) and benign tumours (15.3%).Among the germ cell tumours, ER expression was positive in 62.5% cases of mature teratoma while HER2/neu expression was positive in only 12.5% cases of mature teratoma. None of the sex cord stromal tumours showed positive expression of ER and HER2/neu.

Conclusions: Positive expression of estrogen receptors is seen predominantly in surface epithelial malignancies and in mature teratoma. It proves the mitogenic role of estrogen in ovarian tumours. Her-2 neu was expressed mainly in malignant tumours. This suggests their carcinogenic role. This also helps in differentiating borderline and malignant tumours.


Epithelial ovarian tumours, ER, Her2/neu

Full Text:



Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433.

Soegaard M, Frederiksen K, Jensen A, Høgdall E, Høgdall C, Blaakaer J, et al. Risk of ovarian cancer in women with first degree relatives with cancer. Acta Obstet Gynecol Scand. 2009;88(4);371-2.

Mondal SK, Ranjana, Chowdry SR. Histological pattern and clinical evaluation of 957 ovarian neoplasm: a 10 year study in a tertiary hospital of Eastern India Indian J cancer. 2011:433-7

Manoja V, Pramood M, Jyothi V, Chandrashekar KP. Clinicopathological study of ovarian tumors: a 2-year study. Int J Scient Study. 2017;5(3):297-302.

Jha R, Karki S. Histological pattern of ovarian tumors and their age distribution. Nepal Med Coll J. 2008;10(2):81-5.

Pilli GS, Sunitha KP, Dhaded AV, Yeni VV. Ovarian tumors a study of 282 cases. J Indian Med Assoc. 2002;100(7) 420-4.

Rashid A, Ayub M, Wazir MS. Research ethics need consideration. J Ayub Med Coll Abbottabad. 2010;22(4):1-2.

Bodal VK, Jindal T, Bal MS1, Bhagat R. A clinico -pathological study of ovarian lesions. RRJMHS. 2014;3(1).

De Sousa Damião R, Fujiyama Oshima CT, Stávale JN, Gonçalves WJ. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. Oncology reports. 2007 Jul 1;18(1):25-32.

Sylvia MT, Kumar S, Dasari P. The expression of immune histochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinic pathologic variables. Indian J Pathol Microbiol. 2012;55:33-7.

Goel S. A comparison study of HER-2/neu oncogene in Benign and malignant ovarian tumors. Int J Scient Study. 2014;2:50-4.